安康处女膜修复后会出血吗安康验孕试纸一条深一条特别特别浅,安康唐筛主要检查什么项目,安康宫颈息肉必须要做手术吗,安康夏天怎么坐月子,安康宫颈手术多少钱,安康阴部瘙痒原因,安康为什么会有豆腐渣样白带

SAN DIEGO (KGTV) - Like Pfizer, Moderna, AstraZeneca, and many others, INOVIO Pharmaceuticals has also raced to develop a COVID-19 vaccine this year.“We’ve been working really hard to move our vaccine through the stages of clinical testing. Some things have taken a little bit longer than we hoped. I think that’s kind of always the case when you’re trying to go at great light speed,” said Dr. Kate Broderick, INOVIO Pharmaceuticals Senior VP of Research & Development based in San Diego.Broderick said with funding from the U.S. Department of Defense, the biotech company started its Phase 2 clinical trial evaluating its DNA vaccine candidate, INO-4800.The first U.S. participants received a dose of the experimental vaccine earlier this month. Approximately 400 adults in the U.S. are expected to be enrolled in the trial by the end of the month.“We hope that in the early part of 2021, we’ll be going into a really large Phase 3 trial where we’re asking the question does our vaccine protect against the disease itself,” she said.Broderick said the company hopes to enroll about 6,000 participants initially in its Phase 3 trial once they get the green light to begin.A press release from the company last week stated that “The Phase 3 segment of the INNOVATE remains on partial clinical hold until INOVIO satisfactorily resolves the FDA’s remaining questions related to the CELLECTRA 2000 device that will be used to deliver INO-4800 into the cells of the skin.”Earlier data released from Pfizer and Moderna’s studies showing high vaccine efficacy was positive news for INOVIO.“We feel that we’re in a really good place. There’s eight billion people on the planet, and we’re certainly going to need quite a few different types of vaccines to ensure everybody is protected,” she said. “The Moderna and Pfizer vaccines are RNA vaccines; ours is DNA vaccine”Broderick said one significant benefit of INOVIO’S DNA vaccine candidate is it doesn’t have to be stored in low-temperature freezers, making it easier to ship out worldwide if approved.“In fact, we can keep it at room temperature, sitting on a desk somewhere for a year with no impact,” she said.INOVIO is projecting to have 100 million doses of its vaccine ready in 2021.“With these vaccines being approved, there is definitely an end in sight, but don’t let your guard down too fast,” she said. “Unfortunately, until everyone in the country gets vaccinated, we will still have to adhere to those kinds of annoying things, wearing masks, socially distancing. I know it’s frustrating, especially before the holidays, but just keep yourself safe and the people you love safe.” 2648

SAN DIEGO (KGTV) -- It’s Safely Back to School week on ABC 10News and we’re talking about issues that impact education during this pandemic. On July 29, ABC 10News anchor Ben Higgins and special guest Dr. Joi Spencer, Interim Dean & Professor at the USD School of Leadership and Education Sciences, discuss racial justice in education. 347

SAN DIEGO (KGTV) - In an effort to help solve the homeless problem, the San Diego County Board of Supervisors voted unanimously Tuesday to approve a program that will provide million in financing for seven affordable housing projects.The new development will add 503 units."This is a game changer," says Supervisor Ron Roberts, who championed the proposal along with Supervisor Dianne Jacob. "For the people that need this, this will be a godsend."The money comes from the Innovative Housing Trust Fund, which was created in 2017 to help provide gap financing to developments that can add affordable multi-family rental housing.Many of the units from the first seven projects will be earmarked for the homeless, veterans, people with disabilities or mental illness, families and seniors."For a family of 4 earning just over 70,000 dollars, they won't pay more than 1,900 dollars a month," Roberts says. "You can't find enough bedrooms for a family of four at 1,900 dollars in San Diego."The seven projects will be spread out throughout the county with two in the Otay Mesa/San Ysidro area, two in Vista and one each in Poway, San Marcos and the Southcrest neighborhood of San Diego.All of the projects are expected to be completed by December of 2021. 1288

SAN DIEGO (KGTV) — In some of the most severe cases of COVID-19, doctors are finding it’s not the coronavirus making people critically ill.It’s their own immune system, and a San Diego-based biotech company thinks it has an answer.La Jolla-based INmune Bio announced Tuesday it has FDA approval to begin a Phase 2 clinical trial on its inflammation fighting drug, Quellor.In many of the sickest COVID patients, doctors have noticed their blood is filled with high levels of immune proteins called cytokines. Cytokines act as messengers between cells and the virus can cause them to go haywire, setting off what’s known as a cytokine storm.In a cytokine storm, the body’s immune system starts to attack its own cells and tissues rather than the virus. During the Spanish Flu of 1918, many of the deaths were caused by cytokine storms.“You need to control the cytokine storm to keep patients from getting sick,” said INmune Bio’s CEO Dr. R.J. Tesi.There are several different types of cytokines. A drug undergoing testing in a federal trial with remdesivir targets a cytokine called beta interferon.The San Diego biotech’s drug Quellor suppresses a very specific cytokine called soluble tumor necrosis factor, which Dr. Tesi calls “the master cytokine” because of its role in triggering other immune proteins.Dr. Tesi said this particular cytokine may contribute to another troubling issue with COVID-19: blood clotting.“When they write the history of COVID-19, the clots are going to be the bad guy,” Dr. Tesi said. “These blood clots go off everywhere and they gum up the works. They make it so the lungs can't work. They make it so the kidneys can't work. They make it so the heart is screwed up. Make it so you have strokes.”INmune Bio, which is publicly traded but has just six full-time employees, is hoping its drug can address both the blood clots and the inflammation.The company plans to enroll 366 hospitalized COVID-19 patients for a Phase 2 trial to see if intervention with Quellor can keep people off ventilators and out of the ICU. 2053

SAN DIEGO (KGTV) - Memorial Day weekend will see the most travelers out and about than in the last 12 years.More than 41.5 million Americans will be traveling this weekend, a five percent jump from last year, according to AAA. The increase in nearly 2 million travelers also means longer delays. Transportation analytics company INRIX predicts travel delays could be up to three times longer than normal in some areas of the country.The worst times to hit the roads, rails, or the sky will be Thursday and Friday, as commuters and weekend travelers mix, AAA says.BEFORE YOU HEAD OUT: Check updated San Diego traffic conditions"Drivers should expect congestion across a greater number of days than in previous years, with the getaway period starting on Wednesday, May 23. Our advice to drivers is to avoid peak commute times in major cities altogether – traveling late morning or early afternoon – or plan alternative routes," Graham Cookson, head of research at INRIX, said.The majority of travelers will be on the road, about 36.6 million drivers. Another 3.1 million will take to the air to travel and 1.8 million will travel by train, bus, or cruise.RELATED: With gas prices up, is flying the better alternative to driving this Memorial Day Weekend?AAA says drivers will pay the most expensive Memorial Day weekend prices since 2014, while on average prices for air travel, car rentals, and mid-range hotels are lower than previous years.So where is everyone going? AAA says travelers will be heading to mainly warmer destinations: 1572